Promising results for AMD treatment with targeted radiotherapy

Stereotactic radiotherapy (SRT) seems to offer a safe and efficacious treatment for neovascular age-related macular degeneration (AMD), with patients achieving a statistically significant reduction in ranibizumab retreatment after 24 months, according to Timothy L Jackson PhD, FRCOphth.

Dr Jackson presented the results of the INTREPID study, the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy (IRay™, Oraya Therapy) in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD.

A total of 21 sites in five European countries participated in the trial with a total enrolment of 230 patients. Of this group, 226 received the allocated treatments of 16 Gray (N=74), 24 Gray (N=73) or sham SRT (N=79).